Home > Healthcare > Biotechnology > Bioservices > Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market Share

Report ID: GMI5689
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cell & Gene Therapy Manufacturing Services Market Share

The global market is characterized by a diverse array of companies offering a range of manufacturing services and technologies. Promising players including Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Merck KGaA, WuXi AppTec, Catalent, Inc., Charles River Laboratories International, Inc., and Samsung Biologics dominate the market with their comprehensive service portfolios, advanced technologies, and global presence. These companies offer a comprehensive suite of services, including process development, GMP manufacturing, analytical testing, and regulatory support, catering to the needs of cell and gene therapy developers across the globe. Factors such as technological advancements, regulatory landscape, and strategic alliances continue to shape the competitive dynamics of the market.

Cell & Gene Therapy Manufacturing Services Market Companies

Prominent players operating in the cell & gene therapy manufacturing services industry include:

Boehringer Ingelheim International GmbH
Bluebird Bio, Inc.
Catalent, Inc.
Charles River Laboratories International, Inc.
Merck KGaA
Miltenyi Bioindustry (Miltenyi Biotec)
Samsung Biologics
Takara Bio Inc.
Thermo Fisher Scientific Inc
WuXi AppTec Co., Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cell & gene therapy manufacturing services industry was valued at USD 5.9 billion in 2023 and is projected to record a CAGR of 18.9% between 2024 – 2032, attributed to biotechnological advancements, which hold promise in treating various diseases such as genetic disorders and cancers.

In 2023, the biopharmaceutical companies segment held 69.4% share in the cell and gene therapy manufacturing services market, attributed to their significant investments in R&D, as well as their extensive expertise in drug discovery and development.

North America cell & gene therapy manufacturing services market is anticipated to record a CAGR of 18.1% through 2032, attributed to the regions growing participation in related R&D, rising cancer cases, as well as a large number of contract development manufacturing organizations.

Catalent, Inc., Charles River Laboratories International, Inc., Merck KGaA, Miltenyi Bioindustry (Miltenyi Biotec), Samsung Biologics, and Takara Bio Inc.